INTRODUCTION
Renal fine needle aspiration (FNA) is an excellent test for the diagnosis of radiographically detected lesions in selected patients. Renal FNA can reliably distinguish the majority of benign from malignant lesions, renal cell carcinoma (RCC) from other lesions, including urothelial carcinoma and metastases, and can allow subtyping of RCC. Nevertheless, in the past decade pathologists have acquired more knowledge, especially regarding individual subtypes of RCC. [1] [2] [3] [4] Many of these newer subtypes of RCC either require or are much easier to diagnose with additional ancillary testing, [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] and increasingly tumors with mixed features are being recognized. 17, 18 No specific prognostic markers are available for RCC, although the correct identification of the specific subtype of RCC does more clearly define the prognosis of the patient. Currently, it is unclear to what extent ancillary testing is either necessary or appropriate for renal FNA. Although it is possible to diagnose a wide variety of unusual subtypes of RCC with ancillary testing in renal FNA, at present the therapeutic options remain similar, so the consequences of failing to identify an unusual type of RCC are limited. As a result, at present it is perfectly reasonable to diagnose most RCCs with relatively few ancillary tests and to favor a particular subtype, such as "RCC, favor papillary type." However, this situation is likely to change. There are multiple trials that are focused on adjuvant and neoadjuvant therapies that are subtype-specific, and in the future it is likely that cytologists will need to be able to reliably distinguish between these different entities. This review focuses on a pattern based approach to diagnosing renal FNA to determine which ancillary tests are most appropriate.
BACKGROUND
Most patients with suspicious renal masses should go directly to surgery without the need for presurgical biopsy. However, there is a growing list of indications for biopsy to further characterize a subset of renal masses before definitive therapy is undertaken (either clinical follow-up for lesions that are likely benign or resection/ablation for lesions that are suspicious for malignancy based on radiographic or clinical findings). Resection/ablation can include radical nephrectomy, total nephrectomy, partial nephrectomy, and ablation with a wide variety of agents, including chemicals and radiofrequency.
The indications for renal FNA [19] [20] [21] [22] [23] [24] [25] [26] include:
1. avoiding resection in patients who may not be candidates (i.e., metastasis, high stage, surgically unstable, benign lesions) or patients who are choosing active surveillance 27-29 ; 2. triage in radiographically indeterminate lesions, usually cysts; and 3. surgical planning for partial rather than radical nephrectomy 30 (small lesions, young patients, familial syndromes (Vin Hippel Lindau syndrome, Tuberous Sclerosis), decreased renal function.
Although FNA is both accurate and sufficient for diagnosing most common RCCs, most of the unusual RCCs require additional tissue for testing, meaning that the use of cell blocks and core needle biopsies are likely to become more critical, primarily to ensure adequate tissue for testing.
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RCC
RCC remains the most common diagnosis in renal FNA. The most common subtypes of RCC are shown in Table 1 . [42] [43] [44] For the cytologist, these subtypes are important because the diagnostic criteria are different for each subtype, although these criteria do overlap each other.
Nevertheless, a wide variety of newer subtypes of RCC have been described, most of which have not been characterized on FNA 44, 45 ; a partial list is given in Table 2 . Many of these newer subtypes require ancillary studies for diagnosis. These ancillary studies include both immunohistochemistry and molecular studies, which can be approached with a variety of tests (cytogenetics, fluorescence in situ hybridization [FISH] , next-generation sequencing [NGS]). Our approach to ancillary testing is detailed below.
PATTERN 1. CELLS WITH ABUNDANT PREDOMINANTLY CLEAR CYTOPLASM
This is far and away the most common pattern encountered in renal FNA, and the most common diagnosis is clear cell/conventional RCC (Fig. 1) . A summary of the additional ancillary testing that may be of value is given in Table 3 . Immunohistochemistry for Pax8 (to rule out metastases, urothelial carcinoma, and xanthogranulomatous pyelonephritis), Hale's colloidal iron (to rule out chromophobe RCC), and cytokeratin 7 (CK7) (to rule out papillary RCC and chromophobe RCC) are often enough to allow most clear cell/conventional tumors to be correctly classified. Cancer Cytopathology August 2018 The unusual tumor most likely to mimic a clear cell tumor is a TFE3-or TFEB-mutated tumor (Fig. 2) . [46] [47] [48] A subset of these tumors has also been described under the name microphthalmia transcription factor (MiTF) family translocation-associated tumors. There are a variety of different mutations involving the TFE genes, and whether these tumors should be grouped together or separated into discrete categories is not yet entirely clear. For the purposes of this review, we consider this group of tumors together. In general, a TFE3 FISH is the best test for most of these tumors, but often is not available. TFE3 and or TFEB immunohistochemistry is also good but can be nonspecific. Cathepsin K is highly specific for TFE3 tumors but is not sensitive. In the absence of TFE3, TFEB, or cathepsin K staining, keratin and epithelial membrane antigen (EMA) staining are often negative or only focally positive in these tumors. This may be the first clue that the tumor being examined is not a typical clear cell/conventional RCC.
Alternatively, molecular studies (FISH, NGS) can be used to look for deletions of chromosome 3p at the von Hippel Lindau gene [49] [50] [51] [52] [53] 
PATTERN 2. CELLS WITH ABUNDANT PREDOMINANTLY GRANULAR CYTOPLASM
A summary of the settings in which additional ancillary testing may be of value is given in Table 4 (see also Fig. 3 ). Oncocytoma is far and away the most important but also the most difficult diagnosis to make. There is no stain that allows the ruling in of oncocytoma, thus the diagnosis is always one of exclusion. Oncocytomas can be difficult to distinguish from chromophobe RCC. In addition, most hybrid oncocytoma/chromophobe tumors that can be seen both sporadically and in association with syndromes such as Birt-Hogg-Dube syndrome 18 cannot be reliably distinguished from oncocytoma except on resection. As such, the diagnosis of oncocytoma on FNA is controversial. In a recent survey, only 65% of genitourinary experts were willing to make the diagnosis of oncocytoma even on a core needle biopsy. 58 Nevertheless, we strongly believe the in the appropriate setting making this diagnosis can significantly improve the medical care of patients. In general, oncocytic lesions in young and otherwise healthy patients should be excised, so there is little advantage to making a definitive diagnosis in this setting. However, in the case of an elderly patient with multiple comorbidities, making a definitive diagnosisor at least strongly suggesting it-can allow the patient's medical care team to leave the kidney lesion alone and focus on more important medical issues.
How, then, should one make this diagnosis? We recommend excluding both chromophobe RCC and clear cell/conventional RCC. Compared with oncocytoma, chromophobe RCC has cells arranged as broad trabeculae rather than rounded nests, more prominent nuclear size and shape variation, and darker chromatin. In laboratories that can perform a reliable Hale's colloidal iron stain, this is far and away the best stain for chromophobe RCC. However, many laboratories have trouble with this stain, and consequently the International Society of Urologic Pathologists recommends the use of CK7 Cancer Cytopathology August 2018 instead. 4 In this setting, diffuse staining for CK7 (and CK20 as well) is more common than the focal staining seen in oncocytoma, but our experience with these stains has been disappointing. In particular, when it is unclear whether a patient has an oncocytoma or chromophobe RCC, staining with CK7 almost always yields an intermediate result. Using a CD117 stain is the easiest way to rule out a clear cell/conventional RCC (positive in oncocytoma, negative in clear cell conventional RCC).
In the absence of any positive immunohistochemical studies, the most reliable method to recognize oncocytoma is architecture, either on the cell block or core needle biopsy. The vast majority of oncocytomas have a nested architecture that is distinctly different from the broad trabeculae seen in chromophobe carcinoma or the 66 Oncocytomas have also been associated with complex I enzyme deficiency and mutations of mitochondrial DNA, but this may not be specific enough to use in clinical practice. [67] [68] [69] [70] [71] [72] [73] [74] An uncommon tumor that can also resemble oncocytoma on cytology is an oncocytic papillary tumor. 75 Identification of papillae on a cell block or core needle biopsy is the only way to achieve this diagnosis. We have seen 2 such cases; in these cases, papillae were not present on the direct smear, and CK7 staining was only focally positive.
The most common other pattern with granular cytoplasm is an aspirate with cells with granular cytoplasm and marked atypia, in particular diffusely prominent nucleoli. In this setting, the most common differential is between clear cell/conventional carcinoma and a wide range of newer subtypes, including medullary carcinoma, 76 
PATTERN 3. RENAL ASPIRATES WITH SCANT CELLS
The most important thing about scant renal FNAs is to never diagnose them as "positive for malignancy" (Table 5 ). In almost all cases, a suspicious diagnosis will have the exact same clinical outcome (resection), and there are several benign lesions (cystic nephroma, angiomyolipoma) that can strongly mimic malignancies but are benign. Aspirates of these mimics are often hypocellular. However, there is no defined number of cells that are needed to diagnose a lesion as "positive for malignancy." We have found that angiomyolipomas often result in unsatisfactory aspirates that appear to have scant stroma or cells with nonspecific features. However, sometimes these essentially nondiagnostic specimens will stain with HMB45, which is a strong clue to the diagnosis. As a result, we routinely get an HMB45 on all scant nondiagnostic renal cell aspirates. The use of other ancillary tests in this scenario is limited.
Finally, at present there are no useful defined adequacy criteria for renal FNA. In practice, a specimen is adequate if a specific diagnosis or differential can be reached.
PATTERN 4. RENAL ASPIRATE WITH "ATYPICAL" STROMA
Both RCC and angiomyolipoma can have chunks of cellular stroma that can be difficult to characterize and diagnose (Table 6, Fig. 3 ). In general, when faced with this situation, the edges of the chunks should be examined for the rounded cells of RCC. Keratin, EMA, and HMB45 can be very helpful in sorting out these lesions. Cancer Cytopathology August 2018 Less commonly, a sarcomatoid RCC can also have atypical stroma. Identification of the round cell and sarcomatoid areas, along with keratin and EMA reactivity, is necessary to make this diagnosis; there must be a sarcomatoid component, not just difficult-to-characterize stroma associated with a typical RCC. In general, a definitive diagnosis of sarcomatoid RCC should not be made unless the sarcomatoid component consists of isolated cells that are easy to visualize.
PATTERN 5. RENAL ASPIRATE WITH PLEOMORPHIC CELLS
Pleomorphic aspirates in renal FNA are quite common (Table 7 , Fig. 4 ). The majority of such lesions represent clear cell/conventional RCC or RCC unclassified, which are most easily confirmed with Pax8 and keratin/EMA staining. However, the pleomorphic pattern is not specific, and a wide variety of lesions (both benign and malignant) can present with this appearance. Cancer Cytopathology August 2018 Angiomyolipoma, despite being benign, can be quite pleomorphic-especially the epithelioid type, which may have marked nuclear size and shape variation and intranuclear inclusions. This lesion can be confirmed with positive HMB45/MelanA/smooth muscle actin immunohistochemistry. Urothelial carcinoma (GATA3+, often p40 and or p63+) and metastases (history, immunohistochemical profile depends on primary) are also in the differential diagnosis. Much less commonly, renal medullary carcinomas occur predominantly (if not exclusively) in patients with sickle cell disease and are negative for INI and positive for OCT3/4 on immunohistochemistry. 76 Because the pattern is not specific, virtually all cases require some immunohistochemical confirmation.
PATTERN 6. RENAL ASPIRATES WITH MONOMORPHIC CELLS
Cellularity is key when confronted with a monomorphic pattern of bland epithelial (Table 8) Finally, lymphomas (especially low-grade B cell lymphomas) can be quite monomorphic but look distinctly different from most carcinomas. Low-grade B cell lymphoma cells have scant cytoplasm, dark chromatin, relatively round nuclei, and absent to small nucleoli. Immunohistochemistry for LCA, CD20, CD3, CD5, CD23, CD10, CD43, and keratins may be helpful (see separate review of ancillary studies in hematopoietic neoplasms in this issue).
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PATTERN 7. RENAL ASPIRATE WITH PAPILLAE
The most common lesion with papillae is papillary RCC ( Table 9 , Fig. 5 ). However, papillae can be seen in metanephric adenomas, clear cell papillary RCC, TFE3/ TFEB tumors, urothelial carcinomas, and metastases. A good place to start is with Pax8, EMA, and WT1 to Cancer Cytopathology August 2018 distinguish metanephric adenoma (EMA−, WT1+) from papillary (EMA+, WT1−) and clear cell papillary RCC (EMA+, WT1−). CA-9 can then be used to distinguish papillary RCC (negative) from clear cell/conventional RCC, clear cell papillary RCC, and TFE3/TFEB tumors (positive). 78 Stains for TFE3, TFEB, or cathepsin K staining (TFE3/TFEB tumors) can also be helpful.
Urothelial carcinomas can also appear papillary but are positive for GATA3. Mucinous and spindle cell tumors can have papillary areas, but these are uncommon. The presence of mucin is perhaps the best clue on cytology to this tumor. [79] [80] [81] Finally, metastatic lesions can be papillary, but should have a history of tumor elsewhere; the staining profile will depend on the site of origin.
Alternatively, molecular studies can be used to separate some of these tumors. Trisomies of chromosomes 7 and 17 are common in papillary carcinoma. [82] [83] [84] [85] Metanephric adenoma typically has a normal karyotype.
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PATTERN 8. RENAL ASPIRATE WITH CELLS WITH LARGE VACUOLES
Cells with large clear vacuoles are uncommon in renal FNA (Table 10 , Fig. 6 ). While they could represent clear cell/conventional RCC, more often they are associated with metastases, angiomyolipoma, xanthogranulomatous pyelonephritis, and less commonly urothelial carcinoma. Stains for Pax8, HMB45/MelanA/smooth muscle actin, CD68, keratin, and GATA3 are a good starting point. A B
PATTERN 9. PREDOMINANTLY CYSTIC LESIONS
Approximately 70% to 85% of all renal lesions are cysts; only 1% to 4% are atypical cysts or cystic RCCs, [92] [93] [94] [95] [96] [97] [98] usually of the clear cell or papillary type. 99, 100 The pretest probability that a renal cyst is malignant depends, in part, on the radiologic appearance. Cysts are classified according to the Bosniak system. [101] [102] [103] [104] [105] [106] [107] Most lesions are category 1 (benign); category 4 lesions are frankly malignant and are resected directly; and categories 2 and 3 are indeterminate. Between 5% and 57% of indeterminate cysts are malignant.
Most aspirates of cystic renal lesions result in only proteinaceous debris and macrophages (CD68+), and the sensitivity for cystic RCC in Bosniak category 2-3 leisons is low (10%-25% at best). 93, 94, [108] [109] [110] [111] [112] [113] [114] [115] [116] [117] [118] [119] [120] [121] A keratin stain to highlight epithelial cells may be helpful, but even when atypical it can be difficult to distinguish atypical cyst lining cells from cystic RCC. Nevertheless, even if only a few atypical cells are seen, a "suspicious" diagnosis is appropriate given that it would be truly unusual to see more than this in a truly cystic renal mass.
On the other hand, cysts from patients on renal dialysis for renal failure [122] [123] [124] [125] and patients with adult polycystic kidney disease, an autosomal dominant disease, can develop papillary hyperplasia, 126 and distinction between this hyperplasia and carcinoma is not possible by way of FNA. The best approach is to avoid aspirating cysts in these patients, but if a lesion is aspirated and atpyical papillary groups are found, a diagnosis of "suspicious" rather than "positive" is prudent.
Finally, urologists will aspirate benign, Bosniak category 1 cysts specifically for symptomatic relief. Finding anything other than macrophages is unusual, but a conservative approach should be taken when interpreting any atypical cells.
CONCLUSION
Ancillary studies will be more and more important in evaluating FNAs of the kidney as more and more RCC subtype-specific adjuvant and neoadjuvant therapies are developed. The best use of both immunohistochemical and molecular ancillary studies is often best determined by the cytologic pattern seen in the aspirate.
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